5/14/2013 9:01:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Elixir Medical Corporation begins enrolling patients in a new trial to compare its DESyne Nx Novolimus-eluting coronary stent system to Medtronic's equivalent. With a green-light from the FDA, Elixir Medical Corporation will move forward with its Excella III pivotal trial to review its DESyne Nx Novolimus-eluting coronary stent system. Elixir plans to enroll patients at 50 clinical locations and will use the trial results to support its upcoming premarket approval application. The Excella III study will compare DeSyneNx treatment to Medtronic's (NYSE:MDT) Resolute Zotarolimus-eluting coronary stent system. Results in the Excella II trial last year resulted in CE Mark approval for Elixir's treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by